Corporate Update

AI SummaryClose X

ImmuPharma PLC has provided a corporate update regarding its P140 partnership discussions, now expecting a deal to be completed in 2026 rather than by the end of 2025 due to the detailed nature of negotiations with potential partners, including top global pharmaceutical companies. The company's financial position remains strong, with its cash runway extending well into Q4 2026, bolstered by R&D tax credits, warrant exercises, and enhanced receipts of approximately £2 million from the Lanstead Capital agreement, representing a 7% increase over the original subscription. ImmuPharma has no intention to raise further funds and aims to strengthen its cash position through commercial partnerships.

Disclaimer*

Companies

Immupharma (IMM)
UK 100

Latest directors dealings